We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+104.8%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$189M
AUM Growth
–
Cap. Flow
+$127M
Cap. Flow %
67.2%
Top 10 Hldgs %
55.62%
Holding
62
New
61
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$19.9M
2
KURA icon
Kura Oncology
KURA
+$9.14M
3
BBIO icon
BridgeBio Pharma
BBIO
+$7.48M
4
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$6.35M
5
XLRN
Acceleron Pharma
XLRN
+$5.28M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 80.89%
2 Miscellaneous 16.94%
3 Financials 1.08%
4 Consumer Staples 0.6%
5 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIDX
1
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$29.6M 15.69%
+225,000
New +$19.9M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
$15M 7.93%
+40,000
New +$14.2M
CRIS icon
3
Curis
CRIS
$3.32M
$11.9M 6.29%
+3,625
New +$4.35M
BBIO icon
4
BridgeBio Pharma
BBIO
$14.7B
$11M 5.84%
+155,000
New +$7.48M
KURA icon
5
Kura Oncology
KURA
$1.17B
$8.49M 4.5%
+260,000
New +$9.14M
VINC
6
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$8.43M 4.47%
+20,150
New +$6.35M
RCKT icon
7
Rocket Pharmaceuticals
RCKT
$416M
$5.76M 3.05%
+105,000
New +$3.83M
XLRN
8
DELISTED
Acceleron Pharma
XLRN
$5.76M 3.05%
+45,000
New +$5.28M
OCUL icon
9
Ocular Therapeutix
OCUL
$2.34B
$4.55M 2.41%
+220,000
New +$3.27M
CERE
10
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$4.48M 2.37%
+270,000
New +$3.51M
STRO icon
11
Sutro Biopharma
STRO
$341M
$4.34M 2.3%
+20,000
New +$3.31M
ARKG icon
12
PUT
ARK Genomic Revolution ETF
ARKG
$2B
$3.73M 1.98%
+40,000
New +$3.19M
IMVT icon
13
Immunovant
IMVT
$8.08B
$3.46M 1.84%
+75,000
New +$3.47M
SNDX icon
14
CALL
Syndax Pharmaceuticals
SNDX
$1.85B
$3.35M 1.77%
+150,500
New +$3.12M
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.29M 1.74%
+45,000
New +$3.34M
NAUT icon
16
Nautilus Biotechnolgy
NAUT
$117M
$3.25M 1.73%
+300,000
New +$3.16M
SNCE
17
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$3.2M 1.7%
+15,000
New +$3.12M
ZYME icon
18
Zymeworks
ZYME
$2.14B
$3.07M 1.63%
+65,000
New +$3.02M
OBIO icon
19
Orchestra BioMed
OBIO
$285M
$2.56M 1.36%
+200,000
New +$2.28M
KDNY
20
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.38M 1.26%
+150,000
New +$2.26M
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$141B
$2.36M 1.25%
+10,000
New +$2.29M
MORF
22
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.27M 1.2%
+67,500
New +$1.99M
MREO
23
Mereo BioPharma
MREO
$43.5M
$2.24M 1.19%
+625,000
New +$1.57M
ATNX
24
DELISTED
Athenex, Inc. Common Stock
ATNX
$2.21M 1.17%
+10,000
New +$2.46M
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.2M 1.16%
+10,000
New +$2.16M
1
2 3

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Affinity Asset Advisors, which disclosed 62 positions worth $189M. Its ten largest holdings account for 56% of the portfolio.

Its largest position is Eidos Therapeutics, Inc. Common Stock: 225,000 shares worth $29.6M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q4 2020 buy was Eidos Therapeutics, Inc. Common Stock: 225,000 shares worth $29.6M.
  • Affinity Asset Advisors's ten largest holdings make up 56% of its $189M portfolio in Q4 2020.
  • Affinity Asset Advisors disclosed 62 positions in Q4 2020, its first 13F filing on record.

Based on Affinity Asset Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.